

RECEIVED  
CENTRAL FAX CENTER

DEC 15 2005

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application Number : 10/511,756 Confirmation No. 4938  
Applicant(s) : Bergmann et al.  
Filed : May 25, 2005  
Tech Cntr/AU : 1646  
Examiner : NA  
Entitled : Uses of Carbamoyl Phosphate Synthetase for the Diagnosis of  
Inflammatory Diseases and Sepsis  
Attorney Reference : 121778-04341933  
Customer Number : 43569

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

**CERTIFICATION OF FACSIMILE TRANSMISSION UNDER 37 C.F.R. §1.8**

Sir:

I hereby certify that the following papers are being transmitted by facsimile to the Office of Initial Patent Examination (OIPE), Filing Receipt Corrections Office, at the U.S. Patent and Trademark Office at (571)273-8300 on the date shown below:

- Request for Correction of Official Filing Receipt; and
- Copy of Official Filing Receipt mailed December 15, 2005.

Respectfully Submitted,

MAYER BROWN ROWE &amp; MAW LLP

Date: December 15, 2005

By.

  
Bouvier Afshar

Intellectual Property Group  
1909 K Street, N.W.  
Washington, D.C. 20006  
(202) 263-3000 Telephone  
(202) 263-3300 Facsimile

**Total Pages in Facsimile Transmission: 4**

RECEIVED  
CENTRAL FAX CENTER

DEC 15 2005

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application Number : 10/511,756 Confirmation No. 4938  
Applicant(s) : Bergmann et al.  
Filed : May 25, 2005  
Tech Cntr/AU : 1646  
Examiner : NA  
Entitled : Uses of Carbamoyl Phosphate Synthetase for the Diagnosis of  
Inflammatory Diseases and Sepsis  
Attorney Reference : 121778-04341933  
Customer Number : 43569

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

**REQUEST FOR CORRECTED OFFICIAL FILING RECEIPT**

Sir:

Attached is a copy of the Official Filing Receipt in the above-identified application for which  
issuance of a corrected Official Filing Receipt is respectfully requested.

The noted errors occurred as the following data was:

☒ incorrectly entered

and/or

☐ omitted.

- Error in**
1. ☐ Applicant Name
  2. ☐ Applicant Address
  3. ☒ Title
  4. ☐ Filing Date
  5. ☐ Serial Number
  6. ☐ Foreign Priority Data
  7. ☐ Domestic Priority Data
  8. ☐ Other:

- Correct data**
- 1.
  - 2.
  3. Uses of Carbamoyl Phosphate Synthetase for the  
Diagnosis of Inflammatory Diseases and Sepsis
  - 4.
  - 5.
  - 6.
  - 7.
  - 8.

It is understood that the U.S. Patent & Trademark Office no longer charges a fee for the  
correction of an Official Filing Receipt; however, in the event that a fee is necessary, authorization is  
hereby given to charge any fee deficiencies, or to credit any fee overpayments, to Deposit Account  
No. 503-121.

Respectfully Submitted,

MAYER BROWN ROWE &amp; MAW LLP

Date: December 15, 2005

Intellectual Property Group  
1909 K Street, N.W.  
Washington, D.C. 20006  
(202) 263-3000 Telephone  
(202) 263-3300 Facsimile

Attachment: Official Filing Receipt with indicated correction(s)

By:

  
Paul L. Sharer  
Registration No. 36,004

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

**CONFIRMATION NO. 4938**

## FILING RECEIPT



Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

**Andreas Bergmann, Berlin, GERMANY;  
Joachim Struck, Berlin, GERMANY;  
Monika Uhlein, Berlin, GERMANY;**

**B.R.A.H.M.S Aktiengesellschaft, Hennigsdorf, GERMANY**

**This application is a 371 of PCT/EP03/03939 04/15/2003**

EUROPEAN PATENT OFFICE (EPO) 020088415 04/19/2002

**Early Publication Request: No**

PAGE 3/4 \* RCVD AT 12/15/2005 4:36:41 PM [Eastern Standard Time] \* SVR:USPTO-EFXRF-6/27 \* DNIS:2738300 \* CSID:000 \* DURATION (mm-ss):01-26

*Synthetase*

Uses of carbamoyl phosphate ~~synthesis (cpg 1) and the fragments thereof~~ for the diagnosis of inflammatory diseases and sepsis

**Preliminary Class**

530

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (i)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).